Champions Oncology to Present at The MicroCap Conference on April 10th in New York City at the Essex House

Apr 3, 2018 9:34:28 AM / by Paul McGarry

Hackensack, NJ – April 3, 2018 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that management will be presenting at this year’s MicroCap Conference on Tuesday, April 10, 2018 at 9:30am.

Read More →

Champions Oncology Reports Quarterly Revenue of $5.1 Million

Mar 16, 2018 11:50:20 AM / by Paul McGarry

Company Generates Positive Cash Flow from Operations; Reiterates Expectations for Revenue Growth of at Least 20% for Fiscal Year 2018

Hackensack, NJ – March 15, 2018 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the third fiscal quarter and nine months ended January 31, 2018.

Read More →

Champions Oncology to Participate at the 30th Annual ROTH Conference

Feb 26, 2018 9:15:48 AM / by Paul McGarry

Hackensack, NJ – February 26, 2018 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that management will participate at the 30th Annual Roth Conference and will conduct one-on-one meetings.

Read More →

Motivated Patients with ROS1 Cancer Initiate Global Research Study

Feb 20, 2018 10:38:47 AM / by Paul McGarry

Patients with a rare tumor help drive a novel clinical study developed and launched by the Addario Lung Cancer Medical Institute with Champions Oncology

SAN CARLOS, Calif. and Hackensack, NJ (February 20, 2018) — The Addario Lung Cancer Medical Institute (ALCMI), Champions Oncology (NASDAQ: CSBR) and the ROS1ders announce the commencement of a global study to gain a deeper understanding of ROS1-positive cancer. The study is developing patient-derived xenografts (PDX) models for ROS1-fusion driven cancers to understand what drives tumor development, therapeutic response and acquired resistance to enable the development of new and more effective therapies against this under-studied molecular subset of cancer.

Read More →

Champions Oncology Reports Record Quarterly Revenue of $5.2 Million

Dec 12, 2017 11:08:16 AM / by Mark Weinstein

Quarterly operating profit driven by double-digit revenue growth

Hackensack, NJ – December 7, 2017 – Champions Oncology, Inc. (Nasdaq : CSBR) engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the second fiscal quarter and six months ended October 31, 2017.

Read More →

Champions Oncology announces $2 million award from the National Cancer Institute (NCI) to develop and evaluate prostate cancer PDX models

Sep 26, 2017 2:53:02 PM / by Mark Weinstein

HACKENSACK, NJ - September 26, 2017 - Champions Oncology, Inc. (NASDAQ : CSBR) a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, today announced the signing of a competitive contract through the government’s Small Business Innovation Research (SBIR) program. The contract is in response to Topic 355 – Cell and Animal-Based Models to Advance Cancer Ethnic Health Disparity Research. Champions’ direct-to-Phase II proposal, entitled “Metastatic Prostate Cancer Patient Derived Xenograft Modeling; A New Operating Paradigm”. The contract is a 2-year, $2 million project.  Champions’ network of collaborating sites will contribute to this project.

Read More →

Champions Oncology announces publication highlighting clinical correlation between patient-derived xenograft (PDX) model responses and patient responses to oncology therapies

Sep 18, 2017 8:42:51 AM / by Mark Weinstein

HACKENSACK, NJ - September 18, 2017 - Champions Oncology, Inc. (NASDAQ : CSBR) a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, today announced the publication entitled “Patient-derived xenografts (PDX) effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors” in the journal Annals of Oncology.   Annals of Oncology is published by the European Society for Medical oncology (ESMO), the leading European professional organization for medical oncology in Europe.  Building on earlier clinical correlation data, this study further demonstrates that PDX models accurately predict patient response to oncology drugs with remarkable 85% positive predictive value.

Read More →

Champions Oncology Reports Record Quarterly Revenue of $5 Million

Sep 15, 2017 12:37:57 PM / by Mark Weinstein

37.1% year-over-year revenue increase

Hackensack, NJ – September 14, 2017 – Champions Oncology, Inc. (Nasdaq : CSBR) engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the first quarter ended July 31, 2017.

Read More →

Champions Oncology Announces Strategic Collaboration with AstraZeneca to Develop Unique Cohorts of Patient-Derived Xenograft (PDX) Models

Aug 21, 2017 1:22:51 PM / by Mark Weinstein

HACKENSACK, NJ - August 21, 2017 /PRNewswire/ - Champions Oncology, Inc. (NASDAQ : CSBR) a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, today announced a strategic collaboration with AstraZeneca to develop novel cohorts of PDX models. These models will be used in AstraZeneca’s oncology R&D programs in breast and lung cancer, in addition to being added to Champions’ existing TumorGraft bank for translational oncology research for academic and industry customers. Champions’ global network of collaborating sites will be leveraged to support this multi-year initiative.

Read More →

Champions Oncology Announces Research Collaboration with The Addario Lung Cancer Medical Institute to Develop Unique Cohort of Patient-Derived Xenograft (PDX) Models

Aug 18, 2017 8:30:53 AM / by Mark Weinstein

HACKENSACK, N.J - August 18, 2017 /PRNewswire/ - Champions Oncology, Inc. (NASDAQ : CSBR) a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, today announced a collaboration with The Addario Lung Cancer Medical Institute “ALCMI” to develop a novel cohort of PDX models in patients with ROS1 gene rearrangement. These models will further expand Champions’ TumorGraft bank offerings in non-small cell lung cancer for translational oncology research for academic and industry customers.  Champions’ global infrastructure will be leveraged to support this multi-year program.

Read More →